TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10090436
Drug: Oxaprozin 1200
Normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaprozin 1200 mg QD
Study: 24762631
Drug: Colonoscopy administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colonoscopy administration of fecal microbiota transplant (FMT)
Study: 24750689
Drug: Dietary behavioural
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary behavioural modification treatment without exercise
Study: 30037361
Drug: Budesonide MDI
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide MDI 320 μg
Study: 30037361
Drug: Budesonide MDI
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide MDI 160 μg
Study: 8845402
Drug: HSV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV vaccine
Study: 8222874
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 400 mg three times daily for 10-21 days
Study: 11172152
Drug: Chloroquine treatment
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine treatment
Study: 16159704
Drug: Periprostatic lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periprostatic lidocaine injection (group 2)
Study: 1919633
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of 100 micrograms/m2 IFN gamma and 50 micrograms/m2 TNF alpha every other day (maximally tolerated dose)
Study: 7894919
Drug: Regional nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional nerve block (RNB) with stellate ganglion block and suprascapular nerve block by 1% xylocaine 10 ml
Study: 28205185
Drug: OPERA dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OPERA dietary supplement
Study: 16536811
Drug: 2-week interval
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week interval treatment with pulsed-dye laser (PDL)
Study: 1729971
Drug: Dantrolene Sodium
Normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dantrolene Sodium (Dantrium), 200 mg per day
Study: 16234962
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with teriparatide plus raloxifene
Study: 47280
Drug: Indoprofen 100
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 100 mg
Study: 12140498
Drug: Accelerated emergency
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated emergency department-based strategy with low-molecular-weight heparin and early cardioversion to sinus rhythm
Study: 16027558
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication
Study: 24167545
Drug: Serum transferrin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum transferrin receptor (sTfR)
Study: 24684552
Drug: Belatacept (monthly)
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept (monthly)
Study: 24684552
Drug: Belatacept-based regimens
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept-based regimens supplemented by oral immunosuppression
Study: 28297698
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (365 mg of oral magnesium once daily for 3 months)
Study: 3631260
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 0.1 microgram/min
Study: 19891046
Drug: Standard-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporine
Study: 1329698
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine
Study: 19891046
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus
Study: 9754991
Drug: Intravenous tolcapone
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tolcapone (50 mg)
Study: 21199833
Drug: Satavaptan 50
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 50 mg/day
Study: 29179781
Drug: Low-fat yogurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat yogurt (339 g daily for 9 weeks)
Study: 29373993
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Treatment for Insomnia (BBTI)
Study: 2676651
Drug: Chlorthalidone plus
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone plus metoprolol plus a third drug
Study: 14704543
Drug: T-Flux implant
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-Flux implant
Study: 31926085
Drug: Ciprofloxacin prescription
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin prescription in children
Study: 7648827
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (3.6U over 60 min)
Study: 1877441
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with metoprolol and nifedipine
Study: 30016902
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (3.3 mg IV on days 1-4)
Study: 27353269
Drug: Patient-reported dosing
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported dosing information (PRDI)
Study: 17945539
Drug: Zonisamide (ZNS)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (ZNS) monotherapy, 100, 200, 300, and 400mg/day
Study: 25085539
Drug: Brief Integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Integrated Motivational Intervention plus Treatment As Usual
Study: 3544187
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid (Maalox 70, 280 mmol/day)
Study: 19754498
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention in a geriatric unit (GI) including educational measures and specific actions in seven risk areas (orientation, sensory impairment, sleep, mobilization, hydration, nutrition, drug use).
Study: 28148280
Drug: Adalimumab and
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab and methotrexate combination treatment
Study: 2575521
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg (A200)
Study: 12558470
Drug: Brinzolamide twice
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brinzolamide twice daily plus timolol
Study: 23118648
Drug: Intravenous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rHuEPO 300 units/kg/day
Study: 3318375
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem
Study: 1804649
Drug: SR 33557
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 33557 (300 mg)
Study: 8566267
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of hMG
Study: 15297776
Drug: Prednisolone (PSL)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PSL) increased to 30 mg/day/patient
Study: 31164368
Drug: 6-month hybrid
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month hybrid closed-loop insulin delivery
Study: 10791216
Drug: Mannite solution
Normalized name: Mannit
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannite solution (10%)
Study: 28734043
Drug: Omega-3 fish
Normalized name: Omega-3 Fish Oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fish oil (2.8 g/d)
Study: 1683355
Drug: Intravenous ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ribavirin therapy (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days)
Study: 25527749
Drug: High-phenolic olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-phenolic olive oil (20 mL daily for 6 weeks)
Study: 31915046
Drug: Preoperative Danhong
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Danhong Injection
Study: 31915046
Drug: Postoperative Danhong
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative Danhong Injection
Study: 9839762
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl (5 mg)
Study: 22985607
Drug: Low-dose hydroxychloroquine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydroxychloroquine (100 mg orally, twice weekly, until at least 1 month after normal plasma levels of porphyrin)
Study: 20032538
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy
Study: 19636019
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy, chemotherapy)
Study: 12592245
Drug: Continuous-combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous-combined hormone therapy
Study: 31241782
Drug: Freehand implant
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Freehand implant surgery
Study: 22741027
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control condition consisting of a structured support intervention with psychoeducation and scheduled weekly contacts online for 10 weeks.
Study: 9156046
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test (0.15 U/kg body weight) in diabetic smokers
Study: 4877736
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust extract in a carbol saline solution
Study: 11715663
Drug: Essential phospholipids
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential phospholipids (EPL) administered intravenously, 50 mg every 6 hours for 2 weeks
Study: 8025207
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment alone (Group A)
Study: 21189915
Drug: (S) Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (S) Atenolol 25 mg once daily
Study: 31383564
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy alone (control group)
Study: 31214997
Drug: Trelagliptin 100
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Trelagliptin 100 mg once weekly
Study: 23017618
Drug: Bupropion 150mg
Normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion 150mg twice daily for four weeks
Study: 3300312
Drug: Oral norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral norfloxacin
Study: 27315134
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) (all doses)
Study: 25224595
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy (OC) combined with Caphosol(®)
Study: 3136831
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of recombinant tissue plasminogen activator
Study: 31610337
Drug: Tacrolimus suppositories
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus suppositories (2mg, n=43)
Study: 3882219
Drug: Active-specific immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-specific immunotherapy (ASI) with a syngeneic tumor cell:bacillus calmette-Guerin (BCG) vaccine, following surgical resection.
Study: 16582128
Drug: l-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine
Study: 7842343
Drug: Ginsenoside in
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside in total added into the cardioplegic solution
Study: 28099755
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue (insulin detemir/insulin aspart)
Study: 17518923
Drug: Neuromotor task
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromotor task training (NTT), 9 weekly sessions of 30 minutes each
Study: 7723663
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment for 1 year followed by 1 year without treatment (Group 2)
Study: 14728495
Drug: Intelligent IV
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intelligent IV infusion pumps with integrated software for decision support (DS)
Study: 7525055
Drug: CBDCA dose
Normalized name: CBDCA
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CBDCA dose intensities for each dose level: I (185 mg/m2), II (328 mg/m2), III (567 mg/m2), IIIa (465 mg/m2), Level IV (468 mg/m2).
Study: 15219195
Drug: GPIIb-IIIa antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GPIIb-IIIa antagonists (abciximab)
Study: 16005691
Drug: Carvedilol test
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol test formulation from Laboratórios Biosintética Ltda
Study: 26131753
Drug: Arteriovenous coupler
Normalized name: Complera
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arteriovenous coupler therapy
Study: 3436485
Drug: Iron protein
Normalized name: Iron Protein Succinylate
DrugBank: Iron protein succinylate (DB11209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron protein succinylate (80 mg Fe3+)
Study: 15968231
Drug: Short-term family
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term family therapy (10 sessions over 6 months)
Study: 1473919
Drug: Iopamidol administered
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopamidol administered intravenously
Study: 6685641
Drug: Prior endocrine
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior endocrine therapy non-responders
Study: 6685641
Drug: Prior endocrine
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior endocrine therapy responders
Study: 30572524
Drug: TMBCZG low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMBCZG low-dose group (1 tablet and placebo 2 tablets, twice per day)
Study: 9797599
Drug: Reduced osmolarity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced osmolarity oral rehydration solution (224 mosmol/l)
Study: 8575497
Drug: Finasteride treatment
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride treatment
Study: 17071935
Drug: GEM 1000
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM 1000 mg/m(2) and VNR 25 mg/m(2) on days 1 and 8 (GV arm)
Study: 17071935
Drug: GEM 1000
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM 1000 mg/m(2) and PTX 125 mg/m(2) on days 1 and 8 (GT arm)
Study: 25436225
Drug: Scoliosis-specific exercise
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scoliosis-specific exercise treatment
Study: 27524882
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wPTX) plus valproic acid (VPA)
Study: 11429003
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (2 g daily for 2-3 months) following 14-21 days of intravenous ganciclovir (5 mg/kg b.i.d.)
Study: 8181883
Drug: Transdermal nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitrate therapy (0.4 mg/h)
Study: 30679095
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin 338 (I338)
Study: 17909953
Drug: Flebogamma 5%
Normalized name: Flebogamma 5% 5g Solution for Injection
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flebogamma 5% DIF administered at a dose of 300‐600 mg/kg every 21‐28 days for 12 months
Study: 25173754
Drug: Infliximab therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab therapy
Study: 9106017
Drug: Clarithromycin at
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin at 15 mg/kg per day divided into two equal doses for 10 days
Study: 31993781
Drug: Ofatumumab (OFA)
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab (OFA) 1500 mg/1.73 m2
Study: 20124169
Drug: Conventional-dose radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose radiation therapy (70.2 GyE)
Study: 7554338
Drug: Topical salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical salbutamol
Study: 25107879
Drug: telcagepant 140
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 140 mg
Study: 21457238
Drug: telcagepant 280
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 280 mg
Study: 8353547
Drug: Antibiotic plus
Normalized name: Triple Antibiotic Plus
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic plus laser therapy (group II)
Study: 27727138
Drug: Interactive online
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive online curriculum with weekly reading assignments (GROUP 1)
Study: 26558724
Drug: MVA-B vaccine
Normalized name: MVA-BN-brachyury-TRICOM vaccine
DrugBank: MVA-BN-brachyury-TRICOM vaccine (DB17424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-B vaccine
Study: 30235286
Drug: VSV-Gag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSV-Gag vaccine (3.4 ⊆ 107 PFU) given at 6 months after the initial vaccination.
Study: 17993028
Drug: Crest Vivid
Normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crest Vivid White whitening dentifrice used twice daily
Study: 11773839
Drug: 3-minute daily
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-minute daily treatments for 2 weeks before surgery (Group B)